Diana M. Escolar
Plus aucun poste en cours
Profil
Diana M.
Escolar is the founder of CINRG, which was founded in 2000.
She held the title of Director from 2000 to 2007.
Dr. Escolar's former jobs include Director-Pediatric Neuromuscular Program at Children's National Hospital, Associate Professor at The Johns Hopkins University from 2010 to 2017, Chief Medical Officer at Akashi Therapeutics Inc from 2011 to 2017, Chief Medical Officer at Avrobio, Inc. in 2021, Chief Medical Officer at Viridian Therapeutics, Inc. from 2019 to 2021, and Associate Professor at George Washington University School of Medicine & Health.
Dr. Escolar received a doctorate degree from Universidad de Buenos Aires.
Anciens postes connus de Diana M. Escolar
| Sociétés | Poste | Fin |
|---|---|---|
| AVROBIO, INC. | Chief Tech/Sci/R&D Officer | 26/10/2021 |
| VIRIDIAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Akashi Therapeutics Inc
 Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Chief Tech/Sci/R&D Officer | 01/09/2017 |
| The Johns Hopkins University | Corporate Officer/Principal | 01/01/2017 |
| CINRG | Founder | 01/01/2007 |
Formation de Diana M. Escolar
| Universidad de Buenos Aires | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AVROBIO, INC. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Children's National Hospital (District of Columbia)
 Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Health Services |
| CINRG | |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Health Technology |
